Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
about
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
P2860
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
@en
type
label
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
@en
prefLabel
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
@en
P2093
P2860
P356
P1476
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
@en
P2093
A V Danilov
J J Shatzel
O J T McCarty
T G DeLoughery
P2860
P304
P356
10.1111/JTH.13651
P577
2017-02-09T00:00:00Z